Identification of sex‐specific biomarkers predicting new‐onset heart failure
Abstract Aims Heart failure (HF) is common in both men and women, yet disease pathophysiology, presentation, and progression differ between sexes. Studies addressing whether biomarkers predict new onset HF sex‐specifically are scarce. This study therefore aims to test the sex‐specificity of 252 prot...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-10-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.13476 |
| _version_ | 1818738068690042880 |
|---|---|
| author | Anne Raafs Job Verdonschot João Pedro Ferreira Ping Wang Timothy Collier Michiel Henkens Jens Björkman Alessandro Boccanelli Andrew L. Clark Christian Delles Javier Diez Arantxa González Nicolas Girerd J. Wouter Jukema Florence Pinet Patrick Rossignol Thomas Thum Nicolas Vodovar Rudolf A. deBoer Vanessa vanEmpel Jan A. Staessen Mark Hazebroek John Cleland Faiez Zannad Stephane Heymans |
| author_facet | Anne Raafs Job Verdonschot João Pedro Ferreira Ping Wang Timothy Collier Michiel Henkens Jens Björkman Alessandro Boccanelli Andrew L. Clark Christian Delles Javier Diez Arantxa González Nicolas Girerd J. Wouter Jukema Florence Pinet Patrick Rossignol Thomas Thum Nicolas Vodovar Rudolf A. deBoer Vanessa vanEmpel Jan A. Staessen Mark Hazebroek John Cleland Faiez Zannad Stephane Heymans |
| author_sort | Anne Raafs |
| collection | DOAJ |
| description | Abstract Aims Heart failure (HF) is common in both men and women, yet disease pathophysiology, presentation, and progression differ between sexes. Studies addressing whether biomarkers predict new onset HF sex‐specifically are scarce. This study therefore aims to test the sex‐specificity of 252 protein biomarkers for new‐onset HF. Methods and results A matched case–control design in patients selected from cohorts within the HOMAGE consortium was used. Cases (new‐onset HF, n = 562) and controls (n = 780) were matched for cohort (PREDICTOR, HEALTH‐ABC, & PROSPER), follow‐up time (defined as time from entry to incident HF), and age. Incident HF was defined as first hospitalization for HF. Targeted plasma proteins (n = 252) were measured using Proximity Extension Assay technology from O‐link. To look for sex differences for new onset HF, we adjusted for cohort, age, and baseline clinical parameters. At baseline, women had a biomarker profile reflecting activated metabolism and immune responses. However, none of the biomarkers had a significant interaction with sex in predicting new onset HF, but four biomarkers had a trend towards sex‐specificity (P < 0.013). E‐selectin and interleukin 1 receptor antagonist were more female‐specific, whereas IL17A and CHIT1 tended to be male sex‐specific for incident HF. Conclusions The majority of biomarkers associated with incident HF did not significantly differ between women and men, despite clear differences in biomarkers at baseline. |
| first_indexed | 2024-12-18T01:03:04Z |
| format | Article |
| id | doaj.art-a0903e2857b544a9b4e4d1d58030724b |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-12-18T01:03:04Z |
| publishDate | 2021-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-a0903e2857b544a9b4e4d1d58030724b2022-12-21T21:26:18ZengWileyESC Heart Failure2055-58222021-10-01853512352010.1002/ehf2.13476Identification of sex‐specific biomarkers predicting new‐onset heart failureAnne Raafs0Job Verdonschot1João Pedro Ferreira2Ping Wang3Timothy Collier4Michiel Henkens5Jens Björkman6Alessandro Boccanelli7Andrew L. Clark8Christian Delles9Javier Diez10Arantxa González11Nicolas Girerd12J. Wouter Jukema13Florence Pinet14Patrick Rossignol15Thomas Thum16Nicolas Vodovar17Rudolf A. deBoer18Vanessa vanEmpel19Jan A. Staessen20Mark Hazebroek21John Cleland22Faiez Zannad23Stephane Heymans24Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University Medical Centre P. Debyelaan 25 Maastricht 6229 HX The NetherlandsDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University Medical Centre P. Debyelaan 25 Maastricht 6229 HX The NetherlandsINSERM, Centre d'Investigations Cliniques‐Plurithématique 14‐33, CHRU Nancy, and INSERM U1116, CHRU, F‐CRIN INI‐CRCT (Cardiovascular and Renal Clinical Trialists) Université de Lorraine Nancy FranceDepartment of Clinical Genetics Maastricht University Medical Centre Maastricht The NetherlandsDepartment of Medical Statistics London School of Hygiene and Tropical Medicine London UKDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University Medical Centre P. Debyelaan 25 Maastricht 6229 HX The NetherlandsTataa Biocenter AB Gothenburg SwedenCasa di Cura Quisisana Rome ItalyHull University Teaching Hospitals NHS Trust, Castle Hill Hospital Cottingham UKInstitute of Cardiovascular and Medical Sciences University of Glasgow Glasgow UKProgram of Cardiovascular Diseases CIMA Universidad de Navarra Pamplona SpainProgram of Cardiovascular Diseases CIMA Universidad de Navarra Pamplona SpainINSERM, Centre d'Investigations Cliniques‐Plurithématique 14‐33, CHRU Nancy, and INSERM U1116, CHRU, F‐CRIN INI‐CRCT (Cardiovascular and Renal Clinical Trialists) Université de Lorraine Nancy FranceDepartment of Cardiology Leiden University Medical Centre Leiden The NetherlandsInserm, CHU Lille, Institut Pasteur de Lille, U1167 ‐ RID‐AGE ‐ Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, F‐59000 Lille, and F‐CRIN INI‐CRCT Univ. Lille Lille FranceINSERM, Centre d'Investigations Cliniques‐Plurithématique 14‐33, CHRU Nancy, and INSERM U1116, CHRU, F‐CRIN INI‐CRCT (Cardiovascular and Renal Clinical Trialists) Université de Lorraine Nancy FranceFraunhofer Institute for Toxicology and Experimental Medicine Hannover GermanyInserm UMR‐S 942, F‐CRIN INI‐CRCT, Department of Anaesthesuiology and Intensive Care, Hôpital Lariboisière Université de Paris Paris FranceDepartment of Cardiology University of Groningen, University Medical Centre Groningen Groningen The NetherlandsDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University Medical Centre P. Debyelaan 25 Maastricht 6229 HX The NetherlandsNon‐Profit Research Institute Alliance for the Promotion of Preventive Medicine Mechelen BelgiumDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University Medical Centre P. Debyelaan 25 Maastricht 6229 HX The NetherlandsRobertson Centre for Biostatistics and Clinical Trials Institute of Health and Wellbeing Glasgow UKINSERM, Centre d'Investigations Cliniques‐Plurithématique 14‐33, CHRU Nancy, and INSERM U1116, CHRU, F‐CRIN INI‐CRCT (Cardiovascular and Renal Clinical Trialists) Université de Lorraine Nancy FranceDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM) Maastricht University Medical Centre P. Debyelaan 25 Maastricht 6229 HX The NetherlandsAbstract Aims Heart failure (HF) is common in both men and women, yet disease pathophysiology, presentation, and progression differ between sexes. Studies addressing whether biomarkers predict new onset HF sex‐specifically are scarce. This study therefore aims to test the sex‐specificity of 252 protein biomarkers for new‐onset HF. Methods and results A matched case–control design in patients selected from cohorts within the HOMAGE consortium was used. Cases (new‐onset HF, n = 562) and controls (n = 780) were matched for cohort (PREDICTOR, HEALTH‐ABC, & PROSPER), follow‐up time (defined as time from entry to incident HF), and age. Incident HF was defined as first hospitalization for HF. Targeted plasma proteins (n = 252) were measured using Proximity Extension Assay technology from O‐link. To look for sex differences for new onset HF, we adjusted for cohort, age, and baseline clinical parameters. At baseline, women had a biomarker profile reflecting activated metabolism and immune responses. However, none of the biomarkers had a significant interaction with sex in predicting new onset HF, but four biomarkers had a trend towards sex‐specificity (P < 0.013). E‐selectin and interleukin 1 receptor antagonist were more female‐specific, whereas IL17A and CHIT1 tended to be male sex‐specific for incident HF. Conclusions The majority of biomarkers associated with incident HF did not significantly differ between women and men, despite clear differences in biomarkers at baseline.https://doi.org/10.1002/ehf2.13476ProteomicsIncident heart failureSex differences |
| spellingShingle | Anne Raafs Job Verdonschot João Pedro Ferreira Ping Wang Timothy Collier Michiel Henkens Jens Björkman Alessandro Boccanelli Andrew L. Clark Christian Delles Javier Diez Arantxa González Nicolas Girerd J. Wouter Jukema Florence Pinet Patrick Rossignol Thomas Thum Nicolas Vodovar Rudolf A. deBoer Vanessa vanEmpel Jan A. Staessen Mark Hazebroek John Cleland Faiez Zannad Stephane Heymans Identification of sex‐specific biomarkers predicting new‐onset heart failure ESC Heart Failure Proteomics Incident heart failure Sex differences |
| title | Identification of sex‐specific biomarkers predicting new‐onset heart failure |
| title_full | Identification of sex‐specific biomarkers predicting new‐onset heart failure |
| title_fullStr | Identification of sex‐specific biomarkers predicting new‐onset heart failure |
| title_full_unstemmed | Identification of sex‐specific biomarkers predicting new‐onset heart failure |
| title_short | Identification of sex‐specific biomarkers predicting new‐onset heart failure |
| title_sort | identification of sex specific biomarkers predicting new onset heart failure |
| topic | Proteomics Incident heart failure Sex differences |
| url | https://doi.org/10.1002/ehf2.13476 |
| work_keys_str_mv | AT anneraafs identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT jobverdonschot identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT joaopedroferreira identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT pingwang identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT timothycollier identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT michielhenkens identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT jensbjorkman identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT alessandroboccanelli identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT andrewlclark identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT christiandelles identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT javierdiez identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT arantxagonzalez identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT nicolasgirerd identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT jwouterjukema identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT florencepinet identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT patrickrossignol identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT thomasthum identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT nicolasvodovar identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT rudolfadeboer identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT vanessavanempel identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT janastaessen identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT markhazebroek identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT johncleland identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT faiezzannad identificationofsexspecificbiomarkerspredictingnewonsetheartfailure AT stephaneheymans identificationofsexspecificbiomarkerspredictingnewonsetheartfailure |